PHAR.N0000 Stock Overview
Colombo City Holdings PLC operates in the real estate sector in Sri Lanka.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Colombo City Holdings PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | LK₨52.00 |
| 52 Week High | LK₨52.70 |
| 52 Week Low | LK₨40.30 |
| Beta | 0.065 |
| 1 Month Change | 4.00% |
| 3 Month Change | 1.36% |
| 1 Year Change | -0.95% |
| 3 Year Change | 18.59% |
| 5 Year Change | 44.10% |
| Change since IPO | 396.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHAR.N0000 | LK Real Estate | LK Market | |
|---|---|---|---|
| 7D | 2.0% | 0.2% | 1.5% |
| 1Y | -1.0% | 7.2% | 21.7% |
Return vs Industry: PHAR.N0000 underperformed the LK Real Estate industry which returned 5% over the past year.
Return vs Market: PHAR.N0000 underperformed the LK Market which returned 18.5% over the past year.
Price Volatility
| PHAR.N0000 volatility | |
|---|---|
| PHAR.N0000 Average Weekly Movement | 3.2% |
| Real Estate Industry Average Movement | 5.6% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in LK Market | 6.9% |
| 10% least volatile stocks in LK Market | 2.9% |
Stable Share Price: PHAR.N0000 has not had significant price volatility in the past 3 months.
Volatility Over Time: PHAR.N0000's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 4 | n/a | ambeonholdings.com/real-estate/ |
Colombo City Holdings PLC operates in the real estate sector in Sri Lanka. It lends and maintains commercial properties, as well as leases dwelling flats. The company was formerly known as The Colombo Pharmacy Company PLC and changed its name to Colombo City Holdings PLC in June 2013.
Colombo City Holdings PLC Fundamentals Summary
| PHAR.N0000 fundamental statistics | |
|---|---|
| Market cap | LK₨1.32b |
| Earnings (TTM) | LK₨253.66m |
| Revenue (TTM) | LK₨86.96m |
5.2x
P/E Ratio15.2x
P/S RatioIs PHAR.N0000 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHAR.N0000 income statement (TTM) | |
|---|---|
| Revenue | LK₨86.96m |
| Cost of Revenue | LK₨3.96m |
| Gross Profit | LK₨83.00m |
| Other Expenses | -LK₨170.66m |
| Earnings | LK₨253.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.96 |
| Gross Margin | 95.45% |
| Net Profit Margin | 291.71% |
| Debt/Equity Ratio | 0% |
How did PHAR.N0000 perform over the long term?
See historical performance and comparison